Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IPO keeps Adaptimmune in immunotherapy race as bets pass $1.5bn

This article was originally published in Scrip

Executive Summary

Adaptimmune has become the latest immunotherapy company to raise a large chunk of cash on a US stock exchange, raising an estimated $175m net of expenses through a 6 May offering of American Depositary Shares on Nasdaq. In an area of huge potential but little clinically-proven differentiation, the new money may provide a sufficient financial springboard for the Oxford, UK-based company to throw cash at product development, slugging it out with well-backed US-based firms such as Bellicum Pharmaceuticals, Kite Pharma and Juno Therapeutics, as well as with established competitors such as Novartis.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts